These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target. Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213 [No Abstract] [Full Text] [Related]
4. Adipokine Apelin/APJ Pathway Promotes Peritoneal Dissemination of Ovarian Cancer Cells by Regulating Lipid Metabolism. Dogra S; Neelakantan D; Patel MM; Griesel B; Olson A; Woo S Mol Cancer Res; 2021 Sep; 19(9):1534-1545. PubMed ID: 34172534 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of Apelin/APJ system expression in hepatocellular carcinoma as a function of clinical severity. Cabiati M; Gaggini M; De Simone P; Del Ry S Clin Exp Med; 2021 May; 21(2):269-275. PubMed ID: 33201338 [TBL] [Abstract][Full Text] [Related]
6. Role of Apelin/APJ axis in cancer development and progression. Masoumi J; Jafarzadeh A; Khorramdelazad H; Abbasloui M; Abdolalizadeh J; Jamali N Adv Med Sci; 2020 Mar; 65(1):202-213. PubMed ID: 32087570 [TBL] [Abstract][Full Text] [Related]
7. Apelin (APLN) is a biomarker contributing to the diagnosis and prognosis of hepatocellular carcinoma. Mao X; Zhu X; Pan T; Liu Z; Shangguan P; Zhang Y; Liu Y; Jiang X; Zhang Q Sci Rep; 2024 Sep; 14(1):20441. PubMed ID: 39227683 [TBL] [Abstract][Full Text] [Related]
8. Unraveling the role of ADAMs in clinical heterogeneity and the immune microenvironment of hepatocellular carcinoma: insights from single-cell, spatial transcriptomics, and bulk RNA sequencing. Chen J; Yuan Q; Guan H; Cui Y; Fu C; Wei T; Liu K Front Immunol; 2024; 15():1461424. PubMed ID: 39346916 [TBL] [Abstract][Full Text] [Related]
9. Apelin/APJ system: A potential therapeutic target for endothelial dysfunction-related diseases. Cheng J; Luo X; Huang Z; Chen L J Cell Physiol; 2019 Aug; 234(8):12149-12160. PubMed ID: 30585633 [TBL] [Abstract][Full Text] [Related]
10. KDM5A silencing transcriptionally suppresses the FXYD3-PI3K/AKT axis to inhibit angiogenesis in hepatocellular cancer via miR-433 up-regulation. Ma YS; Wu TM; Qian B; Liu YS; Ding H; Fan MM; Liu JB; Yu F; Wang HM; Shi Y; Gu LP; Li L; Tian LL; Wang PY; Wang GR; Wu ZJ; Zou QF; Ling CC; Fu D J Cell Mol Med; 2021 Apr; 25(8):4040-4052. PubMed ID: 33621431 [TBL] [Abstract][Full Text] [Related]
11. ENG is a Biomarker of Prognosis and Angiogenesis in Liver Cancer, and Promotes the Differentiation of Tumor Cells into Vascular ECs. Shi S; Zhu C; Hu Y; Jiang P; Zhao J; Xu Q Front Biosci (Landmark Ed); 2024 Aug; 29(9):315. PubMed ID: 39344331 [TBL] [Abstract][Full Text] [Related]
12. EYA4 serves as a prognostic biomarker in hepatocellular carcinoma and suppresses tumour angiogenesis and metastasis. Gu F; Yuan S; Liu L; Zhu P; Yang Y; Pan Z; Zhou W J Cell Mol Med; 2019 Jun; 23(6):4208-4216. PubMed ID: 30957411 [TBL] [Abstract][Full Text] [Related]
13. [Effect of Electroacupuncture on Expression of Apelin-APJ System of Cerebral Vascular Endothelial Cell in Rats with Cerebral Infarction]. Yang LH; Du YH; Li J Zhen Ci Yan Jiu; 2017 Feb; 42(1):9-13. PubMed ID: 29071991 [TBL] [Abstract][Full Text] [Related]
14. LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma. Teng F; Zhang JX; Chang QM; Wu XB; Tang WG; Wang JF; Feng JF; Zhang ZP; Hu ZQ J Exp Clin Cancer Res; 2020 Nov; 39(1):235. PubMed ID: 33168027 [TBL] [Abstract][Full Text] [Related]
15. Developing an advanced diagnostic model for hepatocellular carcinoma through multi-omics integration leveraging diverse cell-death patterns. Wang C; Yang G; Feng G; Deng C; Zhang Q; Chen S Front Immunol; 2024; 15():1410603. PubMed ID: 39044829 [TBL] [Abstract][Full Text] [Related]
16. Elucidating the multifaceted role of MGAT1 in hepatocellular carcinoma: integrative single-cell and spatial transcriptomics reveal novel therapeutic insights. Li Y; Chen Y; Wang D; Wu L; Li T; An N; Yang H Front Immunol; 2024; 15():1442722. PubMed ID: 39081317 [TBL] [Abstract][Full Text] [Related]
17. Expression of apelin and apelin receptor (APJ) in porcine ovarian follicles and in vitro effect of apelin on steroidogenesis and proliferation through APJ activation and different signaling pathways. Rak A; Drwal E; Rame C; Knapczyk-Stwora K; Słomczyńska M; Dupont J; Gregoraszczuk EL Theriogenology; 2017 Jul; 96():126-135. PubMed ID: 28532828 [TBL] [Abstract][Full Text] [Related]
18. Apelin-13/APJ system delays intervertebral disc degeneration by activating the PI3K/AKT signaling pathway. Liu W; Niu F; Sha H; Liu LD; Lv ZS; Gong WQ; Yan M Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):2820-2828. PubMed ID: 32271399 [TBL] [Abstract][Full Text] [Related]
19. Apelin inhibition prevents resistance and metastasis associated with anti-angiogenic therapy. Uribesalgo I; Hoffmann D; Zhang Y; Kavirayani A; Lazovic J; Berta J; Novatchkova M; Pai TP; Wimmer RA; László V; Schramek D; Karim R; Tortola L; Deswal S; Haas L; Zuber J; Szűcs M; Kuba K; Dome B; Cao Y; Haubner BJ; Penninger JM EMBO Mol Med; 2019 Aug; 11(8):e9266. PubMed ID: 31267692 [TBL] [Abstract][Full Text] [Related]
20. Ribosomal protein S15a promotes tumor angiogenesis via enhancing Wnt/β-catenin-induced FGF18 expression in hepatocellular carcinoma. Guo P; Wang Y; Dai C; Tao C; Wu F; Xie X; Yu H; Zhu Q; Li J; Ye L; Yu F; Shan Y; Yu Z; Dhanasekaran R; Zheng R; Chen G Oncogene; 2018 Mar; 37(9):1220-1236. PubMed ID: 29242604 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]